Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NASACORT vs BECONASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.
Allergic rhinitis (seasonal and perennial) approved by FDA
FDA-approved: Management of seasonal or perennial allergic rhinitis,Off-label: Nonallergic rhinitis, nasal polyps, adjunctive treatment for sinusitis
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
1.5-3 hours (terminal elimination half-life); no accumulation with once-daily dosing.
Primarily hepatic via CYP3A4; main metabolites are 6β-hydroxytriamcinolone acetonide and 21-carboxylic acid derivative.
Primarily hydrolyzed by esterases in the lung, liver, and plasma to its active metabolite beclomethasone-17-monopropionate (17-BMP). Further metabolism via CYP3A4 to inactive metabolites.
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
Primarily hepatic metabolism; <10% excreted renally as unchanged drug; biliary/fecal excretion accounts for minimal elimination.
Approximately 99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
87% bound to plasma proteins, primarily corticosteroid-binding globulin and albumin.
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; clinical significance: large Vd suggests sequestration in tissues, potentially prolonging retention.
0.5-1.5 L/kg; indicates extensive distribution into tissues.
Intranasal: Absolute bioavailability is approximately 3-5% due to extensive first-pass metabolism and limited absorption from nasal mucosa.
Intranasal: <1% systemic absorption due to extensive first-pass metabolism and local administration.
No dosage adjustment required for renal impairment.
No adjustment required.
No specific dosage adjustment provided; use with caution in severe hepatic impairment, monitor for systemic effects.
No adjustment required.
Ages 2-5: 55 mcg (1 spray) per nostril once daily, maximum 110 mcg (2 sprays) once daily. Ages 6-11: 110 mcg (2 sprays) per nostril once daily, maximum 220 mcg (4 sprays) once daily. Ages 12+: same as adult.
Children 6-11 years: 1 spray (42 mcg) per nostril twice daily; children ≥12 years: same as adult.
No specific adjustment; use lowest effective dose due to potential increased systemic sensitivity; monitor for adverse effects.
No specific adjustment; use lowest effective dose.
No FDA black box warning.
None
Nasal septal perforation,Nasal irritation,Epistaxis,Candida albicans infection,Immunosuppression,Growth suppression in children,Hypothalamic-pituitary-adrenal axis suppression with prolonged use
Risk of suppression of hypothalamic-pituitary-adrenal (HPA) axis with prolonged use at higher than recommended doses,Possible development of localized Candida albicans infections of the nose and pharynx,Caution in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex,Use with caution in patients with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred
Hypersensitivity to triamcinolone acetonide or any excipient,Untreated localized nasal infection
Hypersensitivity to beclomethasone dipropionate or any component of the formulation,Untreated localized nasal mucosal infections (e.g., herpes simplex)
No significant food interactions known. However, grapefruit juice may slightly increase systemic exposure; avoid excessive consumption.
No specific food interactions reported. Beconase is administered intranasally and has negligible systemic absorption, so dietary restrictions are not required.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Nasacort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; avoid unless clearly needed. Second and third trimesters: Limited data; use with caution. Potential fetal risks include orofacial clefts (conflicting data), intrauterine growth restriction, and adrenal suppression in neonates with prolonged maternal use of high doses.
Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major congenital malformations or adverse fetal outcomes. However, the potential for fetal harm cannot be completely ruled out. Trimester-specific risks: First trimester: No evidence of teratogenicity in animal studies at clinically relevant doses, but human data are limited. Second and third trimesters: No increased risk of fetal growth restriction or adrenal suppression reported, but high doses may theoretically affect fetal adrenal function.
It is not known whether triamcinolone acetonide is excreted in human breast milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort is administered to a nursing woman. The M/P ratio is unknown. Low doses via intranasal route are unlikely to produce significant systemic levels; however, consider risk-benefit.
Inhaled beclomethasone is not expected to be present in breast milk in significant amounts due to low systemic bioavailability. The M/P ratio is not available. Manufacturer advises caution, but risk to infant is low. Use while breastfeeding is considered acceptable if maternal benefit outweighs potential risk.
No specific dosing adjustments are recommended for pregnancy based on pharmacokinetic changes. Use the lowest effective dose. Increased plasma volume and altered metabolism during pregnancy may decrease systemic exposure, but intranasal application minimizes systemic absorption. No dose adjustment is typically required, but clinical monitoring for efficacy is advised.
No dose adjustment is generally required for inhaled beclomethasone during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered clearance) are not clinically significant for inhaled corticosteroids due to minimal systemic absorption. However, ensure the lowest effective dose is used to maintain asthma control.
For optimal efficacy, prime the nasal spray by actuating 5 times or until a fine mist appears. If not used for 7+ days, re-prime with 2 actuations. Instruct patient to blow nose gently before use and tilt head slightly forward. Avoid spraying directly onto nasal septum to reduce risk of epistaxis. May cause growth suppression in children; monitor height regularly if long-term use. Onset of action is within 12-24 hours, but maximal effect may take 2-3 weeks.
Beconase (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Onset of action is not immediate; regular use for several days to weeks is required for full effect. Priming the nasal spray with 6 sprays before first use is essential. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. For best results, administer after clearing nasal passages. Systemic absorption is minimal at recommended doses, but monitor for growth suppression in children with prolonged high-dose use.
Use regularly for best results; it may take 2-3 weeks for full effect.,Blow your nose gently before each use to clear nasal passages.,Do not spray directly onto the nasal septum (the wall between nostrils).,Clean the nozzle after each use and replace the cap tightly.,If you miss a dose, skip it and continue with the next scheduled dose; do not double the dose.,Common side effects include nosebleeds, headache, and nasal irritation.,Report persistent nosebleeds, vision changes, or signs of infection (e.g., fever) to your doctor.
Use Beconase regularly as prescribed, not for immediate symptom relief.,Prime the spray with 6 test sprays before first use or if not used for 7 days.,Blow nose gently before dosing to clear nasal passages.,Tilt head forward, insert nozzle into nostril, and spray away from the septum.,Avoid spraying into eyes or on the nasal septum.,Do not exceed recommended dosage; side effects are rare but include nasal irritation or nosebleeds.,Inform your doctor if symptoms do not improve after 3 weeks.,If also using a decongestant spray, use the decongestant first, then wait 10-15 minutes before Beconase.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NASACORT vs BECONASE, answered by our medical review team.
NASACORT is a Intranasal Corticosteroid that works by Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.. BECONASE is a Nasal Corticosteroid that works by Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NASACORT and BECONASE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NASACORT is: 110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.. The standard adult dose of BECONASE is: 1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NASACORT and BECONASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NASACORT is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnan. BECONASE is classified as Category C. Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.